MetaVia Inc. Nasdaq MTVA , a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced that the last patient has completed the final study visit for its Phase 1
Why Is MetaVia Inc. (MTVA) Stock Down Today?
Updated Nov 22, 2026 7:10 AM ET ยท Prev Close $1.07
Session Regime & Catalyst Assessment
68% Signal ConvictionMetaVia Inc. Pulling Back 5.61% on 0.22x Relative Volume
MetaVia Inc. (MTVA) is pulling back 5.61% (-$0.06) to $1.01 on 0.22x average session volume. Relative to benchmarks, MTVA is lagging the S&P 500 by -1.97%. 14-day RSI stands at 38.1, keeping momentum in a bearish regime.
MetaVia Inc. Nasdaq MTVA , a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced that the last patient has completed the final study visit for its Phase 1
Price ($1.01) trades relative to 20-day SMA ($1.24) and 50-day SMA ($1.40).
Market & Sector Relative Strength
MTVA lagging the S&P 500 by -1.97%Options Flow & Execution Desk
Recent MTVA Catalyst Headlines
Verified WireMetaVia Inc. Nasdaq MTVA , a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced positive preclinical data from a head-to-head study comparing Da-1726, a n
MetaVia Inc. Nasdaq MTVA , a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2026, and prov
MetaVia Inc. Nasdaq MTVA , a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced additional positive data from the previously reported interim analysis of
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $1.00 (session support) for directional breakout confirmation.
Technical Regime (MTVA)
BEARISH MA TRENDRetail & Crowd Sentiment
BullishA bullish StockTwits user expresses anticipation for potential volume in $MTVA due to their belief in the company's love for GLP-1 tickers.
About MetaVia Inc.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Da-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 โฆ
Get Instant MTVA Catalyst Alerts
Receive an email alert when MTVA triggers an unusual volume breakout, options sweep, or rating shift.
MTVA Session & Catalyst FAQ
Why is MTVA stock down today?
MetaVia Inc. (MTVA) is pulling back 5.61% (-$0.06) to $1.01 on 0.22x average session volume. Relative to benchmarks, MTVA is lagging the S&P 500 by -1.97%. 14-day RSI stands at 38.1, keeping momentum in a bearish regime.
Is MTVA stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.22x relative volume (low participation). Our multi-factor model currently rates MTVA as HOLD. Review full valuation, quality, and timing signals on the MTVA Buy or Sell Decision Brief โ
What is MTVA's intrinsic value and expected trading range?
At $1.01, MTVA's modeled 1-to-3 session range is $0.95 โ $1.07, with a key inflection level at $1.00 (session support). Compare current price against multi-year cash flow projections in the MTVA Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for MTVA?
RSI at 38.1 reflects soft below-midline momentum. MTVA trades at $1.01 relative to its 20-day SMA ($1.24) and 50-day SMA ($1.40), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.